{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:52:49Z","timestamp":1791229969778,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Gastric neuroendocrine tumors (G-NETs) are rare neoplasms with a favorable survival rate, yet they present a significant risk for second primary malignancies (SPMs). This study aims to estimate the relative risks of SPMs in G-NET survivors, exploring variations across key patient characteristics. Patients diagnosed with G-NETs were identified from the Surveillance, Epidemiology, and End Results database (2000\u20132021). Standardized incidence ratios (SIRs) and excess absolute risks (EARs) were calculated to assess SPM risk stratified by age at diagnosis, gender, race, latency period, marital status, and surgical intervention. Among 5072 G-NET survivors, 912 (18.0%) developed SPMs, with a median interval of 34.3\u00a0months between the diagnoses. The overall SIR for SPMs was 2.09 (95% confidence interval [CI] 1.96\u20132.23), corresponding to an EAR of 145.64 per 10,000 person-years. Increased risks were observed for cancers of the stomach, small intestine, thyroid, hepatobiliary system, pancreas, and esophagus. The highest risk for SPMs occurred within the first 4\u00a0years following G-NET diagnosis (SIR 2.57; 95% CI 2.11\u20133.1), with a gradual decline thereafter. Patients under 50\u00a0years had the highest SIRs, particularly for stomach cancer (SIR 196.28; 95% CI 160.21\u2013238.05). Females exhibited a slightly higher SIR than males. White patients demonstrated the highest risk for stomach cancer, with an SIR of 63.88 (95% CI 57.00\u201371.38). G-NET survivors are at a persistently elevated risk of developing SPMs, particularly within the first 4\u00a0years of diagnosis. Age, gender, and racial factors significantly influence this risk. Personalized surveillance strategies are warranted to address these disparities and reduce SPM incidence.<\/jats:p>","DOI":"10.1007\/s10238-025-01706-y","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:04:10Z","timestamp":1747181050000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The persistent risk of secondary malignancies in gastric neuroendocrine tumor survivors: a population-based analysis"],"prefix":"10.1007","volume":"25","author":[{"given":"Yuheng","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingna","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunda","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"issue":"1","key":"1706_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1001\/archsurg.136.1.49","volume":"136","author":"M Schindl","year":"2001","unstructured":"Schindl M, Kaserer K, Niederle B. Treatment of gastric neuroendocrine tumors: the necessity of a type-adapted treatment. Arch Surg. 2001;136(1):49\u201354.","journal-title":"Arch Surg"},{"issue":"4","key":"1706_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11894-019-0684-7","volume":"21","author":"CR Gluckman","year":"2019","unstructured":"Gluckman CR, Metz DC. Gastric neuroendocrine tumors (carcinoids). Curr Gastroenterol Rep. 2019;21(4):13.","journal-title":"Curr Gastroenterol Rep"},{"issue":"6","key":"1706_CR3","doi-asserted-by":"publisher","first-page":"863","DOI":"10.5009\/gnl220175","volume":"17","author":"Y Kim","year":"2023","unstructured":"Kim Y, et al. Gastric neuroendocrine tumors according to the 2019 World Health Organization grading system: a single-center retrospective study. Gut Liver. 2023;17(6):863\u201373.","journal-title":"Gut Liver"},{"issue":"2","key":"1706_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.5009\/gnl240272","volume":"19","author":"Q Zheng","year":"2025","unstructured":"Zheng Q, et al. Clinical characteristics and long-term outcomes of gastric neuroendocrine tumors. Gut Liver. 2025;19(2):189.","journal-title":"Gut Liver"},{"issue":"21","key":"1706_CR5","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.3390\/cancers16213689","volume":"16","author":"TK Sahin","year":"2024","unstructured":"Sahin TK, et al. Prognostic value of neutrophil-to-eosinophil ratio (NER) in cancer: a systematic review and meta-analysis. Cancers (Basel). 2024;16(21):3689.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"1706_CR6","first-page":"624","volume":"31","author":"DC Guven","year":"2023","unstructured":"Guven DC, et al. Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data. Support Care Cancer. 2023;31(12):624.","journal-title":"Support Care Cancer"},{"issue":"8","key":"1706_CR7","doi-asserted-by":"publisher","first-page":"865","DOI":"10.2217\/fon-2020-0989","volume":"17","author":"AD Ricci","year":"2021","unstructured":"Ricci AD, Rizzo A, Brandi G. DNA damage response alterations in gastric cancer: knocking down a new wall. Future Oncol. 2021;17(8):865\u20138.","journal-title":"Future Oncol"},{"issue":"8","key":"1706_CR8","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.3390\/ijms22083805","volume":"22","author":"K Rihawi","year":"2021","unstructured":"Rihawi K, et al. Tumor-associated macrophages and inflammatory microenvironment in gastric cancer: novel translational implications. Int J Mol Sci. 2021;22(8):3805.","journal-title":"Int J Mol Sci"},{"issue":"17","key":"1706_CR9","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.3390\/cancers14174142","volume":"14","author":"A Rizzo","year":"2022","unstructured":"Rizzo A, et al. Adjuvant PD-1 and PD-L1 inhibitors and relapse-free survival in cancer patients: the MOUSEION-04 study. Cancers (Basel). 2022;14(17):4142.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"1706_CR10","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1001\/jamaoncol.2017.0465","volume":"3","author":"THM Keegan","year":"2017","unstructured":"Keegan THM, et al. Second primary malignant neoplasms and survival in adolescent and young adult cancer survivors. JAMA Oncol. 2017;3(11):1554\u20137.","journal-title":"JAMA Oncol"},{"issue":"3","key":"1706_CR11","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/bjs.10327","volume":"104","author":"A Martling","year":"2017","unstructured":"Martling A, et al. Risk of second primary cancer in patients treated with radiotherapy for rectal cancer. Br J Surg. 2017;104(3):278\u201387.","journal-title":"Br J Surg"},{"issue":"3","key":"1706_CR12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/annonc\/mdw661","volume":"28","author":"AJM Rombouts","year":"2017","unstructured":"Rombouts AJM, et al. Incidence of second tumors after treatment with or without radiation for rectal cancer. Ann Oncol. 2017;28(3):535\u201340.","journal-title":"Ann Oncol"},{"issue":"9","key":"1706_CR13","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1038\/s41416-022-01940-1","volume":"127","author":"I Allen","year":"2022","unstructured":"Allen I, et al. Risk of developing a second primary cancer in male breast cancer survivors: a systematic review and meta-analysis. Br J Cancer. 2022;127(9):1660\u20139.","journal-title":"Br J Cancer"},{"issue":"9","key":"1706_CR14","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1111\/jgh.16201","volume":"38","author":"Z Yang","year":"2023","unstructured":"Yang Z, et al. Risk of second primary malignancies in survivors of pancreatic neuroendocrine neoplasms from 2000 to 2018. J Gastroenterol Hepatol. 2023;38(9):1474\u201384.","journal-title":"J Gastroenterol Hepatol"},{"issue":"8","key":"1706_CR15","doi-asserted-by":"publisher","first-page":"e220337","DOI":"10.1530\/ERC-22-0337","volume":"30","author":"SB Bateni","year":"2023","unstructured":"Bateni SB, et al. Second primary cancers and survival among neuroendocrine tumor patients. Endocr Relat Cancer. 2023;30(8):e220337.","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"1706_CR16","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1159\/000530238","volume":"113","author":"B Russell","year":"2023","unstructured":"Russell B, et al. Second primary malignancies in patients with a neuroendocrine neoplasm in England. Neuroendocrinology. 2023;113(8):811\u201321.","journal-title":"Neuroendocrinology"},{"issue":"11","key":"1706_CR17","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1001\/jamaoncol.2021.4531","volume":"7","author":"SB Bateni","year":"2021","unstructured":"Bateni SB, et al. Incidence and predictors of second primary cancers in patients with neuroendocrine tumors. JAMA Oncol. 2021;7(11):1718\u201320.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1706_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1530\/ERC-11-0315","volume":"19","author":"K Kamp","year":"2012","unstructured":"Kamp K, et al. Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract and pancreas. Endocr Relat Cancer. 2012;19(1):95\u20139.","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"1706_CR19","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.1245\/s10434-014-3774-7","volume":"21","author":"RM Kauffmann","year":"2014","unstructured":"Kauffmann RM, et al. Incidence of additional primary malignancies in patients with pancreatic and gastrointestinal neuroendocrine tumors. Ann Surg Oncol. 2014;21(11):3422\u20138.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1706_CR20","doi-asserted-by":"publisher","first-page":"19748","DOI":"10.1038\/s41598-021-99260-6","volume":"11","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, et al. Second primary malignancy among malignant solid tumor survivors aged 85 years and older. Sci Rep. 2021;11(1):19748.","journal-title":"Sci Rep"},{"issue":"9","key":"1706_CR21","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1080\/14737140.2022.2098718","volume":"22","author":"JE Rodriguez","year":"2022","unstructured":"Rodriguez JE, et al. Immunosenescence, inflammaging, and cancer immunotherapy efficacy. Expert Rev Anticancer Ther. 2022;22(9):915\u201326.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1706_CR22","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.3389\/fimmu.2019.02247","volume":"10","author":"A Aiello","year":"2019","unstructured":"Aiello A, et al. Immunosenescence and its hallmarks: how to oppose aging strategically? A review of potential options for therapeutic intervention. Front Immunol. 2019;10:2247.","journal-title":"Front Immunol"},{"issue":"12","key":"1706_CR23","doi-asserted-by":"publisher","first-page":"e86414","DOI":"10.1371\/journal.pone.0086414","volume":"8","author":"HJ Tsai","year":"2013","unstructured":"Tsai HJ, et al. Second cancers in patients with neuroendocrine tumors. PLoS ONE. 2013;8(12):e86414.","journal-title":"PLoS ONE"},{"issue":"1","key":"1706_CR24","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s10120-019-00982-4","volume":"23","author":"J Ben\u00edtez","year":"2020","unstructured":"Ben\u00edtez J, et al. A genetic origin for acid-base imbalance triggers the mitochondrial damage that explains the autoimmune response and drives to gastric neuroendocrine tumours. Gastric Cancer. 2020;23(1):52\u201363.","journal-title":"Gastric Cancer"},{"key":"1706_CR25","doi-asserted-by":"publisher","first-page":"553110","DOI":"10.3389\/fmed.2021.553110","volume":"8","author":"O Calvete","year":"2021","unstructured":"Calvete O, Reyes J, Ben\u00edtez J. Case report: CMV infection and same mechanism-originated intestinal inflammation compatible with Bowel\/Crohn\u2019s disease is suggested in ATP4A mutated-driven gastric neuroendocrine tumors. Front Med (Lausanne). 2021;8:553110.","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"1706_CR26","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/ijc.32391","volume":"146","author":"S Chattopadhyay","year":"2020","unstructured":"Chattopadhyay S, et al. Second primary cancers in non-Hodgkin lymphoma: family history and survival. Int J Cancer. 2020;146(4):970\u20136.","journal-title":"Int J Cancer"},{"issue":"2","key":"1706_CR27","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1158\/0008-5472.CAN-19-0725","volume":"80","author":"SJ Shin","year":"2020","unstructured":"Shin SJ, et al. Penetrance estimates over time to first and second primary cancer diagnosis in families with Li-Fraumeni syndrome: a single institution perspective. Cancer Res. 2020;80(2):347\u201353.","journal-title":"Cancer Res"},{"issue":"12","key":"1706_CR28","first-page":"1313","volume":"30","author":"B Viner","year":"2019","unstructured":"Viner B, et al. The individual and combined effects of alcohol consumption and cigarette smoking on site-specific cancer risk in a prospective cohort of 26,607 adults: results from Alberta\u2019s Tomorrow Project. Cancer Causes Control. 2019;30(12):1313\u201326.","journal-title":"Cancer Causes Control"},{"issue":"1","key":"1706_CR29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/s12885-021-08098-8","volume":"21","author":"C Wright","year":"2021","unstructured":"Wright C, et al. Young adult cancer risk behaviours originate in adolescence: a longitudinal analysis using ALSPAC, a UK birth cohort study. BMC Cancer. 2021;21(1):365.","journal-title":"BMC Cancer"},{"issue":"2","key":"1706_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000497355","volume":"109","author":"M Cives","year":"2019","unstructured":"Cives M, et al. The tumor microenvironment in neuroendocrine tumors: biology and therapeutic implications. Neuroendocrinology. 2019;109(2):83\u201399.","journal-title":"Neuroendocrinology"},{"issue":"8","key":"1706_CR31","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3390\/cancers11081113","volume":"11","author":"A Sansone","year":"2019","unstructured":"Sansone A, et al. Specific and non-specific biomarkers in neuroendocrine gastroenteropancreatic tumors. Cancers (Basel). 2019;11(8):1113.","journal-title":"Cancers (Basel)"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01706-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01706-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01706-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:47:22Z","timestamp":1764917242000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01706-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1706"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01706-y","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"18 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data used in this study were acquired from a publicly available database. Thus, the approval was not required for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"158"}}